Drug intelligence / Profile preview

Shenghui Granules

Development stage: Unknown
Lead developer: Hubei University of Chinese Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Shenghui Granules is a Traditional Chinese Medicine (TCM) formulation developed by the Hubei University of Chinese Medicine. It is currently being investigated for the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease. As a multi-herbal botanical product, it is intended to improve cognitive function and safety in patients, with clinical trials exploring its potential mechanisms of action in neuroprotection or cognitive enhancement. The formulation is typically administered orally in granule form.

Brand names: Shenghui Granules
Other names: Shenghui

Targets

AcetylcholinesterasePDE4B (3',5'-cyclic-AMP phosphodiesterase 4B)

Beyond the preview

Go deeper on Shenghui Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shenghui Granules.